Cosibelimab
- Generic Name
- Cosibelimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2216751-26-5
- Unique Ingredient Identifier
- PNW7GBB44P
- Associated Conditions
- -
- Associated Therapies
- -
Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab (CK-301) in First Line Metastatic Non-squamous Non-Small Cell Lung Cancer
- First Posted Date
- 2021-03-08
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Checkpoint Therapeutics, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT04786964
- Locations
- 🇹🇭
Research Site, Chiang Mai, Thailand
Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2022-08-22
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT03778073
- Locations
- 🇺🇸
TG Therapeutics Investigational Trial Site, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath